

Mechanism of LncRNA ROR promoting prostate cancer by regulating Akt

X.-Q. ZHAI¹, F.-M. MENG¹, S.-F. HU², P. SUN³, W. XU¹

¹Department of Urology Surgery, Zoucheng People's Hospital, Zoucheng, China

²Department of General Surgery, Zoucheng People's Hospital, Zoucheng, China

³Department of Urology Surgery, Shandong Provincial Hospital, Jinan, China

Xingquan Zhai and Fanmei Meng contributed equally to this work

Abstract. – **OBJECTIVE:** To investigate the expression of long-chain non-coding RNA ROR in prostate cancer (PCa), and to further study its possible underlying mechanisms in prostate cancer.

PATIENTS AND METHODS: Quantitative Real-time polymerase chain reaction (qRT-PCR) was performed to detect the level of LncRNA ROR in 42 pairs of PCa tissues and adjacent normal tissues, and the correlation between ROR level and PCa pathological parameters was also evaluated. Besides, ROR expression in PCa cells was further verified by qRT-PCR, and a knockdown model was constructed using lentivirus in PCa cell lines including PC-3 and C4-2B. Cell counting kit-8 (CCK-8), transwell invasion and cell scratch assay were used to analyze the effect of ROR on the biological function of PCa cells and explore its underlying mechanism.

RESULTS: QRT-PCR results demonstrated that ROR levels in PCa tissues were notably higher than that in normal ones, and the difference was statistically significant. Correlation analysis showed that with lowly-expressed ROR, patients with high ROR level had relatively more advanced tumor stage, higher incidence of lymph node or distant metastasis. Similarly, compared with negative control group, the cell proliferation, invasion and metastasis ability of the knockdown group was significantly decreased. In addition, qRT-PCR results indicated that the expression of Akt, the key protein in the Akt signaling pathway, was significantly reduced in si-ROR cell lines. Furthermore, in vitro experiment revealed that there was a negative regulation between ROR and Akt.

CONCLUSIONS: LncRNA ROR expression is significantly increased in PCa tissues or cells, and is closely associated with PCa stage, lymph node and distant metastasis. Additionally, ROR may promote PCa cell proliferation, invasion and migration by regulating Akt.

Keywords:

Long-chain non-coding RNA, ROR, Akt, Prostate cancer.

Introduction

Prostate cancer (PCa) is the most common malignant tumor in Western developed countries, ranked second in Western countries such as America and Japan¹⁻³. Prostate cancer has a large difference in incidence of different races; for example, PCa has a lower incidence in China than in Western countries^{4,5}. However, after reform and opening up, with the changes in dietary structure and the improvement of diagnostic techniques for prostate cancer, its incidence has been shown an increasing trend in recent years^{6,7}. Prostate cancer has a serious impact on the life expectancy of older men, both domestically and abroad. In particular, China has begun to enter an aging society, so the impact of prostate cancer on Chinese men's lifestyle has become more prominent⁸. However, early symptoms of PCa are concealed, which make many patients have been in a late stage at the time of diagnosis. But if diagnosed early, the harm of PCa to patients can be successfully alleviated, with a good chance of improving therapeutic effect and avoiding long-term complications⁹. With the rapid development of microarray technology and nucleic acid sequencing technology, a large number of non-coding RNA (ncRNA) transcripts have been discovered in eukaryotes, and these ncRNAs have become a crucial part of the intricate regulatory network in the body^{10,11}. According to the length, ncRNA can be divided into long-chain non-coding RNA (LncRNA) and small RNA (siRNA, miRNA, piRNA). The former are RNAs with a transcript length of more than 200 nt, which are specifically expressed between various cells and do not encode proteins themselves, but can regulate the expression level of genes at various levels, initially thought to be the "noise" of transcription^{12,13}. About 66% of the genome is transcribed into non-coding RNA. LncR-

NA creates a complex network regulation system due to its abundance, location and diversity, which has led to the discovery that the differential expression of lncRNA is an important mechanism for the initiation, occurrence and development of cancer¹⁴. At present, gene chip technology is becoming more and more mature; in the mean time, more and more lncRNAs are being found, and the number of lncRNAs associated with prostate cancer is increasing. We have also found 13 lncRNAs with differential expression through gene chip technology¹⁴. Most of them have not been studied, among which, we selected lncRNA ROR as the research object. The biological function and related molecular mechanism of lncRNA ROR remain elusive; let alone its role in the progression of prostate cancer. We firstly identified the differential expression of lncRNA ROR in prostate cancer, and focused on its influence on biological behavior of prostate tumor as well as its mechanism of action. In this study, we analyzed the expression of lncRNA ROR in 42 pairs of PCa and adjacent tissues, and explored the effect of ROR on the biological function of PCa cells. Previous works have proved that ROR is able to accelerate the growth and metastasis of tumor cells, which may affect the development of tumor. In this study, we aimed to investigate the expression of lncRNA ROR in prostate cancer and to clarify its promoting effect on the malignant progression of prostate cancer by regulating Akt.

Patients and Methods

Patients and Prostate Tumor Samples

Prostate tumor tissues and the corresponding adjacent normal tissues were collected from 42 patients who underwent radical resection and routine hematoxylin and eosin (H&E) staining. All the samples were frozen and stored in a refrigerator at -80°C, and subsequently used for RNA extraction. According to the 7th edition of the UICC/AJCC prostate cancer tumor node metastasis (TNM) staging criteria, all patients were diagnosed as PCa by postoperative pathological analysis, and no anti-tumor treatment such as radiotherapy or chemotherapy was performed before surgery. The study was approved by the Ethics Committee of our hospital and all patients had signed informed consent.

Cell Lines and Reagents

Three human PCa cells (PC-3, DU-145, 22RV1, lncap) and one human normal prostate matrix immortalized cell (WPMY-1) were purchased

from American Type Culture Collection (ATCC, Manassas, VA, USA). F-12k and 1640 medium (HyClone, South Logan, UT, USA) and fetal bovine serum (FBS, Gibco, Rockville, MD, USA) were purchased from Life Technologies (Gaithersburg, MD, USA). Cells were cultured in an incubator with 5% CO₂ at 37°C, and the culture medium was F-12k or 1640 containing 10% fetal bovine serum (FBS).

Transfection

The lentivirus containing negative control sequence or the lncRNA ROR knockdown sequence (si-ROR) was purchased from Shanghai Han Company (Shanghai, China). Cells were seeded in 6-well plates and grown to a cell density of 40%, and then transfection was performed according to the manufacturer's instructions. Subsequently, cells were harvested 48 h later for quantitative real-time polymerase chain reaction (qRT-PCR) analysis and function experiments.

Colony Formation Assay

After 48 h of transfection, 200 cells were seeded in each well of a 6-well plate and cultured in complete medium for 2 weeks. The medium should not be replaced as possible in the previous week to avoid cell adhesion and then changed twice a week. After 2 weeks, when cell colony formed, the cells were washed twice with phosphate-buffered saline (PBS) and fixed in 2 ml of methanol for 20 minutes. After removing methanol, cells were washed with PBS and stained with 0.1% crystal violet staining solution for 20 minutes. Next, the cells were photographed and counted under a light-selective environment after washed 3 times with PBS.

Transwell Cell Migration and Invasion Assay

After transfection for 48 hours, cells were digested, centrifuged and resuspended in medium without fetal bovine serum (FBS) to adjust the density to 5×10^5 cells/mL. A cell suspension of 200 μ L (1×10^5 cells) was added to the upper chamber, and 700 μ L of a medium containing 20% fetal bovine serum (FBS) were added to the lower chamber. According to the different migration abilities of each cell line, they were cultured in the incubator for a specific time. Transwell chamber was taken out, washed 3 times with 1 $\times$ PBS, and placed in methanol for 15 min of cell fixation. After the chamber was stained in 0.2% crystal violet for 20 min, the cells on the upper surface of the chamber

were carefully wiped off with water and a cotton swab. The cells were placed under a microscope to observe and photograph, and 10 fields of view were randomly selected for counting and statistical analysis was performed.

Wound Healing Assay

The cells underwent 48 hours of transfection were digested, centrifuged and resuspended in medium without FBS to adjust the density to 5×10^5 cells/mL. The density of the plated cells was determined according to the size of the cells (the majority of the number of cells plated was set to 50,000 cells/well), and the confluency of the cells reached 90% or more the next day. After scratching in the middle of the culture plate, PBS was used to gently rinse cells for 2-3 times and low-concentration serum medium (such as 1% FBS) was added. Lastly, observation was performed after 24 hours. The difference in cell healing ability was judged according to the migration area.

Quantitative Real-Time Phosphate Buffered Saline (qRT-PCR)

Total RNA was extracted from PCa cell lines and tissues using TRIzol reagent (Invitrogen, Carlsbad, CA, USA), and RNA was reverse transcribed into cDNA using Primescript RT Reagent (Takara, Otsu, Shiga, Japan). QRT-PCR reactions were performed using SYBR® Premix Ex Taq™ (Takara, Otsu, Shiga, Japan) and 7500 Plus Real-time PCR System (Applied Biosystems, Foster City, CA, USA). The following primers were used for qRT-PCR reaction: ROR forward: 5'-ACGAGAGGACCGA-3', reverse: 5'-GC-CAAGTTCTAGAT-3'; ROR forward: 5'-TGCCACTGCG-3', reverse: 5'-TAGAAGAA-3'; β -actin: forward: 5'-GCTCACAG-3', reverse: 5'-TACCCA-3'; β -actin: forward: 5'-CCGCGCA-3', reverse: 5'-AGCACAAT-3'; β -actin: forward: 5'-CTGATCCAC-3', reverse: 5'-TGCTGGAA-3'. Data analysis was performed using ABI Step One software and relative expression levels of mRNA were calculated using the $2^{-\Delta\Delta Ct}$ method.

Western Blot Assay

Transfected cells were lysed using cell lysis buffer, shaken on ice for 30 minutes, and centrifuged at $14,000 \times g$ for 15 minutes at 4°C . The protein concentration was calculated by bicinchoninic acid (BCA) Protein Assay Kit (Pierce & Warriner, Rockford, IL, USA). The extracted proteins were separated using a 10% sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) gel and subsequently transfer-

red to a polyvinylidene difluoride membrane (Millipore, Billerica, MA, USA). Western blot analysis was performed according to standard procedures. The primary antibodies were anti-ROR and glyceraldehyde 3-phosphate dehydrogenase (GAPDH), and the secondary antibodies were anti-mouse and anti-rabbit, which were all purchased from Cell Signaling Technology (Danvers, MA, USA).

Statistical Analysis

The continuous variables were analyzed using the *t*-test, while categorical variables were using the χ^2 test or Fisher's exact probability method. Kaplan-Meier method was performed to analyze the prognosis of patients, and the difference between different curves was compared by Log-rank test. The program was processed using the Statistical Product and Service Solutions (SPSS) 22.0 (IBM, Armonk, NY, USA) program and the data was expressed as mean $\pm$ standard deviation ($\bar{x} \pm s$). $p < 0.05$ was considered to be statistically significant.

Results

ROR was Highly Expressed in PCa Tissues and Cell Lines

We examined the level of ROR in 42 pairs of PCa tissues as well as their adjacent tumor-free tissues and PCa cell lines by qRT-PCR. The results showed that ROR expression levels were appreciably increased in PCa tissues compared with adjacent tumor-free tissues. The difference was statistically significant (Figure 1A). Compared with human normal prostate matrix immortalized cells (WPMY-1), ROR was also found notably higher in PCa cells (Figure 1B).

ROR Expression was Correlated with Clinical Stage, Lymph Node and Distance Metastasis in PCa Patients

According to the results of qRT-PCR of 42 pairs of ROR expression in PCa tissues and paraneoplastic ones, the samples were divided into two groups, which were high expression one and low expression one. The number of each group was counted and the relationship between ROR level and age, sex, clinical stage of PCa patients, condition of lymph node or distant metastasis were analyzed. Table I indicated that highly expressed ROR was positively correlated with the above clinical parameters.

Table 1. Association of lncRNA ROR expression with clinicopathologic characteristics of prostate cancer.

Parameters	Number of cases	ROR expression		P-value
		Low (%)	High (%)	
Age (years)				0.780
< 60	15	9	6	
≥ 60	27	15	12	
Gender				0.002
Male	20	12	8	
Female	22	12	10	
T stage				0.044
T1-T2	26	18	8	
T3-T4	16	6	10	
Lymph node metastasis				0.002
No	28	19	9	
Yes	14	5	9	
Distance metastasis				0.002
No	31	22	9	
Yes	11	2	9	

Knockdown of ROR Inhibited Cell Proliferation, Migration and Invasion

To explore the effects of ROR on PCa cell proliferation, migratory and invasive capacity, we first successfully constructed a ROR knockdown model and verified it using qRT-PCR (Figure 2A). Subsequently, we used cell-cloning experiments to investigate the effect of ROR on the proliferation of PCa cells, and found that the proliferation rate of the si-ROR group was significantly lower than that of the NC group (Figure 2B). In addition, using the Transwell migration assay and wound healing test, the number of transmembrane PCa cells was significantly reduced

in the si-ROR group was extensively less than the NC group, suggesting that the migratory ability of cells with down-regulated ROR was inhibited (Figure 2D). Meanwhile, the cells in the si-ROR group also showed a poor healing ability (Figure 2C).

Knockdown of ROR Changed Akt Expression

To analyze the potential mechanisms of Akt and ROR in influencing the malignant progression of PCa, we examined Akt expression in 42 pairs of PCa tissues and their corresponding normal ones using qRT-PCR. The results indicated that




Figure 1. LncRNA ROR was highly expressed in prostate cancer tissues and cell lines. **A**, QRT-PCR was used to detect the differential expression of LncRNA ROR in prostate cancer tissues and adjacent non-tumor tissues; **B**, QRT-PCR was used to detect the expression level of LncRNA ROR in prostate cancer cell lines. Data were expressed as mean $\pm$ SD, * p <0.05, ** p <0.01, *** p <0.001.

compared to adjacent tissue, the expression level of Akt in PCa tissue was considerably elevated, with the difference statistically significant (Figure 3A). Furthermore, ROR level was also notably high in PCa cells compared to WPMY-1 (Figure 3B). Therefore, we analyzed the expression of ROR and Akt both on gene and protein levels in tissues and found a clear correlation between the two (Figure 3C). Next, using qRT-PCR method, we demonstrated that the level of Akt was down-regulated after ROR knockdown (Figure 3D).

Akt Modulated ROR Expression in Human Prostate Cancer Cells

Subsequently, to figure out the regulatory role between ROR and Akt, we transfected an overexpression-plasmid into ROR knockdown-PCa cells. The expression of Akt was detected by qRT-PCR and Western Blot, respectively. Results revealed that overexpression of Akt restored the role of knockdown of ROR in PCa cells (Figure 4A and Figure 4B). Subsequently, through cell cycle experiments, we found that overexpression of Akt




Figure 2. LncRNA ROR affected prostate cancer cell proliferation and invasion and migration. **A**, QRT-PCR validated the transference efficiency of LncRNA ROR after transfection of si-ROR in PC-3 and Lncap cell lines; **B**, Results of cell colony formation assay showed the effect of knockdown of ROR on prostate cancer cell proliferation in PC-3 and Lncap cell lines; **C**, Cell scratch assay was used to detect the effect of knock-downed ROR on the healing ability of prostate cancer cells in PC-3 and Lncap cell lines.

Figure continued




Figure 2. Continued. **D**, Transwell assay was used to detect the effect of knock-down ROR on the ability of cancer cells to invade and migrate in PC-3 and Lncap cell lines. Data were expressed as mean $\pm$ SD, $p < 0.05$.

could counteract the effect of knockdown of ROR on PCa cell proliferation rate (Figures 4C).

Discussion

As a common malignant tumor, PCa's early diagnosis, metastasis, recurrence, and treatment of advanced PCa after surgery have become the focus of current research¹⁻³. Scholars^{4,7,9} have found that lncRNA plays a vital role in various diseases, including tumors. Multiple abnormally expressed-lncRNAs in PCa may play a crucial role in the diagnosis, treatment and prognosis of PCa. Therefore, finding these lncRNAs in PCa and analyzing its correlation with clinical prognosis will help to improve the diagnosis and treatment of PCa, and improve the prognosis of patients.

lncRNAs are a large-scale ncRNAs that can regulate a variety of biological processes. They are widely distributed and generally more than 200 bp in length. However, most of them do not get the ability of encoding proteins due to the lack of a valid open reading frame (ORF)^{9,10}. The role of lncRNA in tumors is still in infancy and has gradually become a hot spot. It has been found that some lncRNAs exert a crucial influence on

the progression of tumors. They are abnormally expressed in various malignant tumors such as liver cancer, lung cancer, and prostate cancer, and have played a considerable role in the occurrence and development of malignant tumors, even some lncRNAs can be used as a marker for tumor diagnosis and prognosis¹¹⁻¹⁴. Therefore, finding abnormal expression of lncRNA in prostate cancer and analyzing its function will help to elevate diagnosis and treat level of prostate cancer and improve the prognosis of patients^{15,16}. Currently, lncRNA related to prostate cancer is being gradually discovered, including PCA3, PCEGM1, etc. These lncRNAs are gradually being applied to clinical diagnosis and prognosis evaluation¹⁷⁻¹⁹. In this study, RNA was extracted from pathologically diagnosed tumor specimens and adjacent normal tissues of patients with prostate cancer, and 13 lncRNAs were found to be associated with prostate cancer by gene chip hybridization screening. Further literature review provided that lncRNA ROR gene is closely related to the development of colorectal and esophageal cancer, but its association with prostate cancer remains elusive^{15,16}. Our research focused on the lncRNA ROR expression in PCa tissues and its role in the development of this tumor. We first verified the level of ROR in 42 pairs of PCa tissues and adja-




Figure 3. Akt was highly expressed in prostate cancer tissues and cell lines. **A**, QRT-PCR was used to detect Akt expression in prostate cancer tissues and adjacent non-tumor tissues; **B**, QRT-PCR was used to detect Akt expression in prostate cancer cell lines; **C**, LncRNA ROR in prostate cancer tissues significantly positively correlated with the expression level of Akt; **D**, QRT-PCR verified the interference efficiency of ROR after transfection of si-ROR in PC-3 and Lncap cell lines. Data were expressed as mean $\pm$ SD. * $p<0.05$, ** $p<0.01$, *** $p<0.001$.

cent tissues, and the results indicated that ROR level was considerably up-regulated and positively correlated with PCa TNM stage, lymph node metastasis and distant metastasis. From this we believe that ROR may play a role in promoting the progression of PCa. To further explore the effects of ROR on the biological function of PCa, we constructed a ROR knockdown model using lentivirus. Cell colony formation experiments, invasion and migration assay and wound healing test showed that ROR exerted an important influence on the occurrence and development of PCa, but its specific molecular mechanism remains unclear. Akt is a serine kinase, also known as protein kinase B (PKB) or A and C related protein kinases

(RAC.PK) because its amino acid composition in kinase activity region is very similar to PKA and PKC^{20,21}. There are three subtypes of Akt, including Akt1, Akt2 and Akt3. Among them, Akt1 is widely present in various tissues. Akt2 is mainly found in insulin-like tissues, while Akt3 is more strictly distributed in the brain and testes^{21,22}. The Akt protein consists of three parts: pleckstrin homology domain (PH domain), the intermediate kinase domain and the carboxy-terminal regulatory region. Among them, the PH domain of Akt is highly similar to that of some other signaling molecules which are capable of binding 3-phosphatidylinositol^{22,23}. In this experiment, in order to clarify whether ROR promotes the progres-




Figure 4. LncRNA ROR could regulate the expression of Akt in prostate cancer tissues and cell lines. **A**, Akt gene levels were detected by qRT-PCR in LncRNA ROR and Akt co-transfected cell lines; **B**, Akt protein levels were detected by western blot test in LncRNA ROR and Akt co-transfected cell lines; **C**, Colony formation experiments examined the role of co-transfection of LncRNA ROR and Akt in regulating prostate cancer cell proliferation. Data were expressed as mean $\pm$ SD, * $p < 0.05$.

sion of PCa by regulating Akt. We found the expression of Akt after knockdown of ROR using Western Blot assay. Results indicated that the expression level of the above protein was drastically after ROR knockdown, suggesting a relationship between ROR and Akt. In addition, we also found that cell rescue experiments that overexpression of Akt counteracted the role of knockdown of ROR in PCa cells. As the research continues to deepen, further understanding of the biological function of Akt gene and its role in the development of tumors will be more conducive to the diagnosis, treatment and prognosis of tumors. This undoubtedly brings good news to many cancer patients and their families, and the new dawn of human conquest of cancer.

Conclusions

We detected the expression level of LncRNA ROR was remarkably upregulated in PCa tissues and cells, and notably correlated with PCa TNM

stage, lymph node or distant metastasis. In addition, LncRNA ROR may have the ability to promote the malignant progression of PCa by regulating Akt.

Conflict of Interest

The Authors declare that they have no conflict of interest.

References

- JEAN-PIERRE G. Advice about screening for prostate cancer with prostate-specific antigen. *J Adv Pract Oncol* 2017; 8: 639-645.
- ALTWAIURY N, SOMANI S, DUFES C. Targeted nonviral gene therapy in prostate cancer. *Int J Nanomedicine* 2018; 13: 5753-5767.
- SMITH ZL, EGGNER SE, MURPHY AB. African-American prostate cancer disparities. *Curr Urol Rep* 2017; 18: 81.
- HEALTH QUALITY ONTARIO. Polaris cell cycle progression test for localized prostate cancer: a health technology assessment. *Ont Health Technol Assess Ser* 2017; 17: 1-75.
- SOHAIL A, SHERIN L, BUTT SI, JAVED S, LI Z, IOBAL S, BE'G OA. Role of key players in paradigm shifts of

- prostate cancer bone metastasis. *Cancer Manag Res* 2018; 10: 1619-1626.
- 6) ANGELES AK, BAUER S, RATZ L, KLAUCK SM, SULTMANN H. Genome-based classification and therapy of prostate cancer. *Diagnostics (Basel)* 2018; 8: 62.
- 7) WANG G, ZHAO D, SPRING DJ, DePINHO RA. Genetics and biology of prostate cancer. *Genes Dev* 2018; 32: 1105-1140.
- 8) YAO M, ROGERS L, SUCHOWERSKA N, CHOE D, AL-DAB-BAS MA, NARULA RS, LYONS JG, SVED P, LI Z, DONG Q. Sensitization of prostate cancer to radiation therapy: Molecules and pathways to target. *Radiother Oncol* 2018; 128: 283-300.
- 9) GUO T, WANG XX, FU H, TANG YC, MENG BQ, CHEN CH. Early diagnostic role of PSA combined miR-155 detection in prostate cancer. *Eur Rev Med Pharmacol Sci* 2018; 22: 1615-1621.
- 10) YANG C, SHEN C, FENG T, LI H. Noncoding RNA in NK cells. *J Leukoc Biol* 2018 Sep 28. doi: 10.1002/JLB.1RU0518-197RR. [Epub ahead of print]
- 11) CORRA F, AGNOLETTI C, MINOTTI L, BALDASSARI F, VOLINIA S. The network of non-coding RNAs in cancer drug resistance. *Front Oncol* 2018; 8: 327.
- 12) KAIKKONEN MU, ADELMAN K. Emerging roles of non-coding RNA transcription. *Trends Biochem Sci* 2018; 43: 654-667.
- 13) ROY S, TRAUTWEIN C, LUEDDE T, RODEBURG C. A general overview on non-coding RNA-based diagnostic and therapeutic approaches for liver diseases. *Front Pharmacol* 2018; 9: 805.
- 14) HE A, HE S, LI X, ZHOU L. ZFAS1: a novel vital oncogenic lncRNA in multiple human cancers. *Cel Prolif* 2018; e12513.
- 15) AIRD J, BAIRD AM, LIM M, McDERMOTT R, FINN SP, GRAY SG. Carcinogenesis in prostate cancer: the role of long non-coding RNAs. *Noncoding RNA Res* 2018; 3: 29-38.
- 16) KLINGE CM. Non-coding RNAs: long non-coding RNAs and microRNAs in endocrine-related cancers. *Endocr Relat Cancer* 2018; 25: R259-R282.
- 17) GIUNCHI F, CICCARESE C, MONTIRONI R, CARPELLI M, LOPEZ-BELTRAN A, CHENG L, LUCH H, MONTAUDO E, FIORENTINO M. Urinary biomarkers for prostate cancer. *Curr Drug Metab* 2017; 18: 723-726.
- 18) DANI H, LOEB S. The role of prostate cancer biomarkers in undiagnosed men. *Curr Opin Urol* 2017; 27: 210-216.
- 19) TANASE CP, COLETTI E, POPEA C, MIHAI, IANCIU AM, NECULA LG, RADA A, ISMAIL C, GHEORGHE R. Prostate cancer genomics: current trends and future perspectives in biomarker discovery. *Oncotarget* 2017; 8: 18497-18506.
- 20) HUNTER X, LIU G, GUO Y, ZHANG Z. The PI3K/AKT pathway in obesity and type 2 diabetes. *Int J Biol Sci* 2018; 14: 1483-1496.
- 21) BAIYUN R, LI S, LIU B, LU J, LV Y, XU J, WU J, LI J, LV Z, ZHANG Z. Nucleolin-mediated PI3K/AKT/Nrf2 signaling pathway ameliorates inorganic mercury-induced cardiac injury. *Ecotoxicol Environ* 2018; 272: 655-661.
- 22) ROGEL JA, WILLOUGHBY JE, BUCHAN SL, LEONARD HJ, THIRDBOROUGH SM, AL-SHAMKHANI A. Akt signaling is critical for memory CD8(+) T-cell development and tumor immune surveillance. *Proc Natl Acad Sci U S A* 2017; 114: E1178-E1187.
- 23) KOUNDOUROU N, POULOGIANNIS G. Phosphoinositide 3-kinase/akt signaling and redox metabolism in cancer. *Front Oncol* 2018; 8: 160.